Who are Peginterferon Alfa's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Low-dose anrikefon, Pegylated IFN- alpha 2b, PEG-IFN-SA /RBV, Peginterferon-α-2a, PEG-Intron + Ribavirin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/peginterferon-alfa.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Peginterferon Alfa — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Peginterferon Alfa (Peginterferon Alfa) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Interferon-alpha. Area: Immunology, Virology, Oncology.

marketed Interferon-alpha Interferon-alpha receptor (IFNAR) Immunology, Virology, Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Peginterferon Alfa (Peginterferon Alfa) — Third Affiliated Hospital, Sun Yat-Sen University. Peginterferon alfa is an interferon-alpha protein conjugated with polyethylene glycol that activates innate and adaptive immune responses to suppress viral replication and inhibit cell proliferation.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Peginterferon Alfa TARGET	Peginterferon Alfa	Third Affiliated Hospital, Sun Yat-Sen University	marketed	Interferon-alpha	Interferon-alpha receptor (IFNAR)
Low-dose anrikefon	Low-dose anrikefon	Peking University First Hospital	marketed	Interferon-alpha analog	Interferon-alpha receptor (IFNAR)
Pegylated IFN- alpha 2b	Pegylated IFN- alpha 2b	Ain Shams University	marketed	Interferon-alpha	Interferon-alpha receptor (IFNAR)
PEG-IFN-SA /RBV	PEG-IFN-SA /RBV	Beijing Kawin Technology Share-Holding Co., Ltd.	phase 3	Pegylated interferon-alpha with nucleoside analog	Interferon-alpha receptor; viral RNA polymerase
Peginterferon-α-2a	Peginterferon-α-2a	Ministry of Health, Malaysia	phase 3	Interferon-alpha, pegylated	Interferon-alpha receptor (IFNAR)
PEG-Intron + Ribavirin	PEG-Intron + Ribavirin	PharmaEssentia	phase 3	Interferon-alpha and antiviral	Interferon receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Interferon-alpha class)

Ain Shams University · 1 drug in this class
Third Affiliated Hospital, Sun Yat-Sen University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Peginterferon Alfa — Competitive Intelligence Brief. https://druglandscape.com/ci/peginterferon-alfa. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing